research use only

Lurbinectedin (PM01183) DNA Minor Groove Binder

Name: Lurbinectedin (PM01183)
Brand: Selleck Chemicals
SKU: S9603
Availability: InStock
Rating: 5 (5 reviews)

Cat.No.S9603

Lurbinectedin, a DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Lurbinectedin inhibits RMG1 and RMG2 cell growth with IC50 of 1.25 nM and 1.16 nM, respectively.

Chemical Structure

Molecular Weight: 784.87

Jump to

Quality Control

Batch: Purity: 99.93%

99.93

Related Targets	HDAC PARP ATM/ATR DNA-PK WRN Topoisomerase PPAR Sirtuin Casein Kinase eIF
Other DNA/RNA Synthesis Inhibitors	CX-5461 (Pidnarulex) SCR7 Favipiravir (T-705) RK-33 EED226 BMH-21 Carmofur Triapine (3-AP) YK-4-279 Halofuginone

Solubility

In vitro
Batch:

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	784.87	Formula	C₄₁H₄₄N₄O₁₀S	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	497871-47-3	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	PM-1183, LY-01017, Tryptamicidin, PM01183			SMILES	CC1=CC2=C(C3C4C5C6=C(C(=C7C(=C6C(N4C(C(C2)N3C)O)COC(=O)C8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	DNA minor groove RMG2 cell growth (Cell-based assay) 1.16 nM RMG1 cell growth (Cell-based assay) 1.25 nM
In vitro	Lurbinectedin exhibits significant antitumor activity toward chemosensitive and chemoresistant CCC cells in vitro. This compound plus SN-38 combination has strong synergistic effects on both the cisplatin-resistant and paclitaxel-resistant CCC cell lines.
In vivo	An examination of mouse CCC cell xenografts reveals that lurbinectedin significantly inhibits tumor growth. This compound plus SN-38 combination results in a significant synergistic effect. Everolimus significantly enhances the antitumor activity of this chemical-based chemotherapies.
References	[1] https://pubmed.ncbi.nlm.nih.gov/26986199/ [2] https://pubmed.ncbi.nlm.nih.gov/20977459/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-09-02)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07328425	RECRUITING	Desmoplastic Small Round Cell Tumor	Italian Sarcoma Group	2025-11-21	PHASE2
NCT07365241	RECRUITING	Small Cell Lung Cancer	AbbVie	2026-07-02	PHASE3
NCT07796100	NOT_YET_RECRUITING	Extensive-Stage Small Cell Lung Cancer	Zai Lab (Shanghai) Co., Ltd.	2026-12-31	PHASE3
NCT07141771	NOT_YET_RECRUITING	SCLC, Extensive Stage	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	2025-12-31	PHASE1; PHASE2
NCT07625644	NOT_YET_RECRUITING	Small Cell Lung Cancer Extensive Stage; Small-cell Lung Cancer; Small Cell Carcinoma; Sclc; SCLC,Extensive Stage; Lung Cancer; Lung Cancer Metastatic; Lung Cancer Stage IV	SystImmune Inc.	2026-06	PHASE3
NCT06681220	RECRUITING	Relapsed Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer	VA Office of Research and Development	2026-02-23	PHASE1; PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):